Sanofi India Receives GST Show Cause Notice for ₹16.4 Crore Demand
Sanofi India Limited received a GST Show Cause Notice dated September 28, 2026, from Gujarat authorities. The notice proposes a demand of ₹16.4 crore for tax, interest, and penalty related to alleged discrepancies in GST filings for FY 2022-23. The company is reviewing the notice and expects no adverse financial impact.
The notice involves a significant amount of ₹16.4 crore, which could potentially impact the company's financials if the demand is upheld. However, the company's assessment that there will be no adverse impact mitigates the impact to medium.
The company has received a notice proposing a tax demand, which is a negative development. However, the company is in the process of responding and does not foresee any adverse impact, which balances the sentiment to neutral.
Sanofi India Limited has received a Show Cause Notice dated 28th September 2026 from the State Tax Officer, Gujarat, concerning Goods and Services Tax (GST) matters for the Financial Year 2022-23. The notice alleges discrepancies between E-Way Bills and GSTR-1 filings, issues with reconciling turnover reported in GSTR-9C versus GSTR-1, short reversal of input tax credit, and availment of certain ineligible input tax credits.
The proposed demand aggregates to ₹16,40,07,641 towards tax, interest, and penalty. The company is currently in the process of responding to the notice after gathering the relevant facts. Sanofi India, in consultation with its tax advisors, is examining the notice and will take appropriate steps, including submitting a reply within the prescribed timeframe. The company does not anticipate any adverse financial or operational impact from this notice.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.